Table 1

Characteristics of patients and controls

CharacteristicsMTX n=50NIP n=44P value
 Age, mean (SD)61.68 (12.4)61.9 (21.5)0.946
 Female, n (%)40 (80)29 (65.9)0.339
 BMI mean, (SD)25.7 (4.0)25.77 (4.5)0.927
Third vaccination
 BNT162b2, n (%)38 (76)44 (100)0.032
 mRNA-1273, n (%)12 (24)0 (0)
Time between blood sampling and third vaccination
 Days between first visit and booster (pre booster), mean (range)10 (0–30)7 (0–36)0.089
 Days between booster and second visit (week 4), mean (range)31 (25–53)27 (17–42)0.001
 Days between booster and third visit (week 12), mean (range)88 (76–129)97 (78–124)0.009
Rheumatic diagnosis
 Rheumatoid arthritis, n (%)36 (72)/
 Psoriatic arthritis, n (%)7 (14)/
 Other, n (%)*7 (14)/
Medication
 MTX-mono, n (%)15 (30)/
 MTX+prednisolone, n (%)12 (24)/
 MTX+TNF-α-inhibitor, n (%)11 (22)/
 MTX+TNF-α-inhibitor+prednisolone, n (%)6 (12)/
 MTX+other, n (%)†6 (12)/
 MTX-dose in mg/week, mean (SD)12.5 (4.2)/
 Prednisolone in mg/day, mean (SD)3.8 (3.3)/
MTX regimen
 MTX continued, n (%)24 (48)/
 MTX pause, n (%)26 (52)/
 Duration of hold (days), mean (SD)19.9 (7.7)/
 Duration of hold before vaccine (days), mean (SD)7.6 (3.9)/
 Duration of hold after vaccine (days), mean (SD)12.4 (7.1)/
  • *Takayasu arteritis, 2 × axial spondylarthritis (ankylosing spondylitis), dermatomyositis/polymyositis, polymyalgia rheumatica, blistering dermatitis, systemic sclerosis.

  • †2x Leflunomide, IL-12/IL-23-Inhibitor, prednisolone/immunglobulins, hydroxychloroquine, IL-17-Inhibitor.

  • BMI, body mass index; MTX, methotrexate; NIP, non-immunosuppressed persons.